Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab vaccine response in healthy participants
NCT05827874Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nipocalimab in myasthenia gravis (MG) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants with a Positive Anti-tetanus toxoid Immunoglobulin G Response at Week 4. Started Apr 2023; status: completed.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05827874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827874.